Total joint arthroplasty in patients with chronic infectious liver disease
The opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant technologies, and improvement of techniques in TJA. Unfortunately, treating this gr...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-06-01
|
Series: | Arthroplasty Today |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352344115000515 |
id |
doaj-f81a83d44f4b4959877e174fbed4bd82 |
---|---|
record_format |
Article |
spelling |
doaj-f81a83d44f4b4959877e174fbed4bd822020-11-25T02:29:30ZengElsevierArthroplasty Today2352-34412016-06-0122697610.1016/j.artd.2015.07.001Total joint arthroplasty in patients with chronic infectious liver diseaseJeremy N. Truntzer, MD0Kalpit N. Shah, MD1Derek R. Jenkins, MD2Lee E. Rubin, MD3Department of Orthopaedics, Stanford University, Stanford CA, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAThe opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant technologies, and improvement of techniques in TJA. Unfortunately, treating this group of patients is not without significant challenges that can stem from both intrahepatic and extrahepatic clinical manifestations. Moreover, many subclinical changes occur in this cohort that can alter hemostasis, wound healing, and infection risk even in the asymptomatic patient. In this review, we discuss the various clinical presentations of chronic infectious liver disease and summarize the relevant literature involving total joint arthroplasty for this population. Hopefully, through appropriate patient selection and perioperative optimization, treating surgeons should see continued improvement in outcomes for patients with chronic infectious liver disease.http://www.sciencedirect.com/science/article/pii/S2352344115000515Total joint arthroplastyHepatitis CHepatitis BCirrhosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jeremy N. Truntzer, MD Kalpit N. Shah, MD Derek R. Jenkins, MD Lee E. Rubin, MD |
spellingShingle |
Jeremy N. Truntzer, MD Kalpit N. Shah, MD Derek R. Jenkins, MD Lee E. Rubin, MD Total joint arthroplasty in patients with chronic infectious liver disease Arthroplasty Today Total joint arthroplasty Hepatitis C Hepatitis B Cirrhosis |
author_facet |
Jeremy N. Truntzer, MD Kalpit N. Shah, MD Derek R. Jenkins, MD Lee E. Rubin, MD |
author_sort |
Jeremy N. Truntzer, MD |
title |
Total joint arthroplasty in patients with chronic infectious liver disease |
title_short |
Total joint arthroplasty in patients with chronic infectious liver disease |
title_full |
Total joint arthroplasty in patients with chronic infectious liver disease |
title_fullStr |
Total joint arthroplasty in patients with chronic infectious liver disease |
title_full_unstemmed |
Total joint arthroplasty in patients with chronic infectious liver disease |
title_sort |
total joint arthroplasty in patients with chronic infectious liver disease |
publisher |
Elsevier |
series |
Arthroplasty Today |
issn |
2352-3441 |
publishDate |
2016-06-01 |
description |
The opportunity for total joint arthroplasty (TJA) in patients with chronic infectious liver disease is rapidly expanding. This is the product of both superior survival of chronic hepatitis patients, evolving implant technologies, and improvement of techniques in TJA. Unfortunately, treating this group of patients is not without significant challenges that can stem from both intrahepatic and extrahepatic clinical manifestations. Moreover, many subclinical changes occur in this cohort that can alter hemostasis, wound healing, and infection risk even in the asymptomatic patient. In this review, we discuss the various clinical presentations of chronic infectious liver disease and summarize the relevant literature involving total joint arthroplasty for this population. Hopefully, through appropriate patient selection and perioperative optimization, treating surgeons should see continued improvement in outcomes for patients with chronic infectious liver disease. |
topic |
Total joint arthroplasty Hepatitis C Hepatitis B Cirrhosis |
url |
http://www.sciencedirect.com/science/article/pii/S2352344115000515 |
work_keys_str_mv |
AT jeremyntruntzermd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease AT kalpitnshahmd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease AT derekrjenkinsmd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease AT leeerubinmd totaljointarthroplastyinpatientswithchronicinfectiousliverdisease |
_version_ |
1724832708005199872 |